Elanco Animal Health (NYSE:ELAN) Lowered to “Buy” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Elanco Animal Health (NYSE:ELAN) from a strong-buy rating to a buy rating in a research report released on Sunday morning.

A number of other research analysts have also issued reports on ELAN. KeyCorp reiterated an “overweight” rating on shares of Elanco Animal Health in a research report on Wednesday, December 10th. Zacks Research cut shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 6th. Morgan Stanley increased their price objective on shares of Elanco Animal Health from $18.00 to $22.00 and gave the company an “equal weight” rating in a report on Thursday, December 18th. Stifel Nicolaus boosted their target price on shares of Elanco Animal Health from $18.00 to $23.00 and gave the stock a “buy” rating in a research note on Wednesday, September 24th. Finally, UBS Group upped their price target on shares of Elanco Animal Health from $25.00 to $27.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $23.78.

Elanco Animal Health Price Performance

NYSE:ELAN opened at $23.47 on Friday. The company has a quick ratio of 1.23, a current ratio of 2.40 and a debt-to-equity ratio of 0.59. Elanco Animal Health has a 52 week low of $8.02 and a 52 week high of $23.89. The stock’s 50-day moving average price is $22.27 and its 200-day moving average price is $19.36. The stock has a market capitalization of $11.66 billion, a PE ratio of 391.20, a price-to-earnings-growth ratio of 3.26 and a beta of 1.87.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.06. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The company had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.09 billion. During the same quarter in the prior year, the firm posted $0.13 EPS. Elanco Animal Health’s quarterly revenue was up 10.4% compared to the same quarter last year. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. As a group, equities analysts expect that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, insider Rajeev A. Modi acquired 4,500 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The stock was bought at an average price of $21.33 per share, with a total value of $95,985.00. Following the purchase, the insider owned 123,082 shares in the company, valued at approximately $2,625,339.06. The trade was a 3.79% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Robert M. Vanhimbergen acquired 6,950 shares of the business’s stock in a transaction on Thursday, December 11th. The stock was acquired at an average price of $21.64 per share, with a total value of $150,398.00. Following the acquisition, the chief financial officer owned 124,233 shares in the company, valued at $2,688,402.12. The trade was a 5.93% increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired 43,450 shares of company stock valued at $937,883 over the last ninety days. 0.89% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ELAN. AlphaQuest LLC increased its holdings in shares of Elanco Animal Health by 13.7% in the third quarter. AlphaQuest LLC now owns 5,953 shares of the company’s stock valued at $120,000 after purchasing an additional 718 shares during the last quarter. Jones Financial Companies Lllp grew its holdings in Elanco Animal Health by 15.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 6,065 shares of the company’s stock valued at $119,000 after buying an additional 798 shares in the last quarter. MTM Investment Management LLC increased its stake in shares of Elanco Animal Health by 5.5% in the 2nd quarter. MTM Investment Management LLC now owns 15,268 shares of the company’s stock worth $218,000 after acquiring an additional 800 shares during the last quarter. US Bancorp DE increased its stake in shares of Elanco Animal Health by 1.9% in the 3rd quarter. US Bancorp DE now owns 43,810 shares of the company’s stock worth $882,000 after acquiring an additional 824 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. raised its holdings in shares of Elanco Animal Health by 80.3% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock worth $42,000 after acquiring an additional 900 shares during the period. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.